Is Evelo Biosciences, Inc. (EVLO) a Buy, Sell, or Hold?
OTC : EVLO
Evelo Biosciences, Inc. — Insider Trades
$0.0001 USD
$0 (0.0%)
- Volume
- 133
- Average Volume
- 577.82
- Market Capitalization
- $1.9K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.16
Insider Activity Summary (Last 12 Months)
Insiders Buying
43
Insiders Selling
36
Amount of Insider Selling
$746.78K
EVLO Insider Buying/Selling by Quarter
EVLO Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-08 | S-Sale | 0.33 | 2023-11-08 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-08 | S-Sale | 0.33 | 2023-11-08 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| GILL SIMBA | director, officer: President & CEO | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| GILL SIMBA | director, officer: President & CEO | 2023-11-08 | S-Sale | 0.33 | 2023-11-08 |
| GILL SIMBA | director, officer: President & CEO | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-08 | S-Sale | 0.33 | 2023-11-08 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-07 | M-Exempt | 0 | 2023-11-08 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-11-02 | S-Sale | 0.33 | 2023-11-03 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| McHale Duncan | officer: Chief Medical Officer | 2023-11-02 | S-Sale | 0.33 | 2023-11-03 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-01 | M-Exempt | 0 | 2023-11-03 |
| Thorell Marella | officer: Chief Financial Officer | 2023-11-02 | S-Sale | 0.33 | 2023-11-03 |
| GILL SIMBA | director, officer: President & CEO | 2023-09-27 | A-Award | 0 | 2023-09-29 |
| GILL SIMBA | director, officer: President & CEO | 2023-09-27 | M-Exempt | 0 | 2023-09-29 |
| GILL SIMBA | director, officer: President & CEO | 2023-09-27 | M-Exempt | 0 | 2023-09-29 |
| GILL SIMBA | director, officer: President & CEO | 2023-09-28 | S-Sale | 3.94 | 2023-09-29 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-09-11 | A-Award | 0 | 2023-09-13 |
| Thorell Marella | officer: Chief Financial Officer | 2023-09-11 | A-Award | 0 | 2023-09-13 |
| McHale Duncan | officer: Chief Medical Officer | 2023-09-11 | A-Award | 0 | 2023-09-13 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-08-08 | S-Sale | 9.51 | 2023-08-09 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-08-08 | S-Sale | 9.51 | 2023-08-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-08-08 | S-Sale | 9.51 | 2023-08-09 |
| Thorell Marella | officer: Chief Financial Officer | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| Thorell Marella | officer: Chief Financial Officer | 2023-08-07 | M-Exempt | 0 | 2023-08-09 |
| Thorell Marella | officer: Chief Financial Officer | 2023-08-08 | S-Sale | 9.51 | 2023-08-09 |
| Horizon Technology Finance Corp | 10 percent owner | 2023-07-11 | 0 | 2023-07-21 | |
| Flagship Ventures Fund IV General Partner LLC | 10 percent owner | 2023-07-11 | P-Purchase | 2.31 | 2023-07-13 |
| Flagship Ventures Fund IV General Partner LLC | 10 percent owner | 2023-07-11 | P-Purchase | 2.31 | 2023-07-13 |
| Flagship Ventures Fund IV General Partner LLC | 10 percent owner | 2023-07-11 | P-Purchase | 2.31 | 2023-07-13 |
| Reynolds Alexander C | director | 2023-07-11 | A-Award | 3.38 | 2023-07-12 |
| Reynolds Alexander C | director: | 2023-07-11 | 0 | 2023-07-12 | |
| Moore Jeffrey R. | director | 2023-07-11 | A-Award | 3.38 | 2023-07-12 |
| Moore Jeffrey R. | director: | 2023-07-11 | 0 | 2023-07-12 | |
| Williams Tonya | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| Gutierrez-Ramos Jose-Carlos | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| Hohneker John | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| McHugh Julie | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| McInnes Iain B. | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| MELAS KYRIAZI THEO | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| Andres Juan | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| Rosiello Robert L. | director | 2023-06-08 | A-Award | 0.11 | 2023-06-12 |
| GILL SIMBA | director, officer: President & CEO | 2023-06-08 | A-Award | 0.97 | 2023-06-12 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-05-23 | S-Sale | 0.1418 | 2023-06-12 |
| McHale Duncan | officer: Chief Medical Officer | 2023-05-08 | S-Sale | 0.1255 | 2023-05-10 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-05-08 | S-Sale | 0.1255 | 2023-05-10 |
| Thorell Marella | officer: Chief Financial Officer | 2023-05-08 | S-Sale | 0.1255 | 2023-05-10 |
| GILL SIMBA | director, officer: President & CEO | 2023-05-08 | S-Sale | 0.1255 | 2023-05-10 |
| GILL SIMBA | director, officer: President & CEO | 2023-05-07 | M-Exempt | 0 | 2023-05-10 |
| Thorell Marella | officer: Chief Financial Officer | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| Thorell Marella | officer: Chief Financial Officer | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-05-07 | M-Exempt | 0 | 2023-05-09 |
| Rosiello Robert L. | director | 2023-04-14 | A-Award | 0.17 | 2023-04-18 |
| Rosiello Robert L. | director: | 2023-04-14 | 0 | 2023-04-18 | |
| GILL SIMBA | director, officer: President & CEO | 2023-02-07 | A-Award | 0.97 | 2023-02-09 |
| GILL SIMBA | director, officer: President & CEO | 2023-02-07 | A-Award | 0 | 2023-02-09 |
| Bodmer Mark | officer: CSO, President of R&D | 2023-02-07 | A-Award | 0 | 2023-02-09 |
| McHale Duncan | officer: Chief Medical Officer | 2023-02-07 | A-Award | 0 | 2023-02-09 |
| Thorell Marella | officer: Chief Financial Officer | 2023-02-07 | A-Award | 0 | 2023-02-09 |
| Plinio Mark D. | officer: Chief Commercial Officer | 2023-01-31 | A-Award | 0.88 | 2023-02-02 |
| CARRIERE STEPHEN J | officer: Principal Accounting Officer | 2023-01-19 | M-Exempt | 0 | 2023-01-23 |
| CARRIERE STEPHEN J | officer: Principal Accounting Officer | 2023-01-19 | M-Exempt | 0 | 2023-01-23 |
| CARRIERE STEPHEN J | officer: Principal Accounting Officer | 2023-01-23 | S-Sale | 1.0604 | 2023-01-23 |
| Char Daniel | officer: General Counsel | 2022-07-19 | A-Award | 0 | 2022-10-14 |
| Zung Jonathan B. | officer: Chief Development Officer | 2022-07-19 | A-Award | 0 | 2022-10-14 |
| Plinio Mark D. | officer: Chief Commercial Officer | 2022-07-29 | A-Award | 1.79 | 2022-10-14 |
| Thorell Marella | officer: Chief Financial Officer | 2022-09-01 | A-Award | 2.29 | 2022-09-01 |
| Thorell Marella | officer: Chief Financial Officer | 2022-09-01 | A-Award | 0 | 2022-09-01 |
| Thorell Marella | officer | 2022-07-13 | 0 | 2022-07-18 | |
| Epstein David R | director: | 2022-06-30 | M-Exempt | 0 | 2022-06-30 |
| MELAS KYRIAZI THEO | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |
| McInnes Iain B. | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |
| McHugh Julie | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |
| Hohneker John | director | 2022-06-09 | A-Award | 2.6 | 2022-06-13 |
| Hohneker John | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |
| Epstein David R | director: | 2022-06-10 | A-Award | 0 | 2022-06-13 |
| Darzi Lord Ara | director | 2022-06-10 | A-Award | 2.02 | 2022-06-13 |
| Darzi Lord Ara | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |
| Darzi Lord Ara | director | 2022-06-09 | A-Award | 2.6 | 2022-06-13 |
| Andres Juan | director | 2022-06-09 | A-Award | 2.6 | 2022-06-13 |
| Andres Juan | director: | 2022-06-09 | A-Award | 0 | 2022-06-13 |